NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/02/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,435.13 mln
Float89.94 mln
Earnings Date08/05/2026
EPS
0.35
Overpriced
P / E
258
Bubble territory
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-3.3
Reliable
1-Year Forecast
88.00
Fairly priced
Relative Strength
86
/ 100
Strongly outperforming
Business Description
Corcept Therapeutics is a US-based pharmaceutical company focused on developing drugs that target the effects of cortisol, a hormone that can cause serious harm when the body produces too much of it. Its main product, Korlym, is an approved oral treatment for adults with Cushing's syndrome whose excess cortisol has led to blood sugar problems and who cannot or did not benefit from surgery. The company also has several additional compounds in various stages of clinical testing, targeting conditions such as liver disease and ALS. Founded in 1998 and based in Redwood City, California, Corcept has built its entire business around understanding and controlling cortisol's role in disease.